Kiniksa Pharmaceuticals officer sells 194k in stock

KNSA Stock  USD 21.13  0.04  0.19%   
About 68% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Kiniksa Pharmaceuticals officer sells 194k in stock

Read at investing.com
Investing News at Macroaxis
  

Kiniksa Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earning

Price To Earning Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

CHRSCoherus BioSciences   24.82   
0%
100.0%
LYRALyra Therapeutics   10.53   
0%
42.0%
VTYXVentyx Biosciences   6.12   
0%
24.0%
KRONKronos Bio   4.44   
0%
17.0%
SPROSpero Therapeutics   1.72   
0%
6.0%
DAWNDay One   1.55   
0%
6.0%
CGEMCullinan Oncology   1.25   
0%
5.0%
PHATPhathom Pharmaceuticals   1.24   
0%
4.0%
GPCRStructure Therapeutics   0.90   
0%
3.0%
REPLReplimune   0.23   
0%
1.0%
COGTCogent Biosciences   0.22   
0%
1.0%
LRMRLarimar Therapeutics   0.16   
0%
1.0%
NUVLNuvalent   0.56   
2.0%
0%
KURAKura Oncology   2.06   
8.0%
0%
NVCTNuvectis Pharma   3.02   
12.0%
0%
GOSSGossamer Bio   4.11   
16.0%
0%
ACLXArcellx   7.39   
29.0%
0%
BOLTBolt Biotherapeutics   7.94   
31.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators